OBI Pharma Granted OBI 833 Patents for Taiwan and Australia

OBI Pharma, Taiwan (4174) announced that it has been granted Taiwan and Australian patents protecting OBI-833, its new cancer vaccine comprised of the Globo H hexasaccharide (Globo H) antigen conjugated to DT-CRM197, a non-toxic, mutated form of diphtheria toxin (DT): “Vaccines with higher carbohydrate antigen density and novel saponin adjuvant.”; Taiwan Patent No. 201429488 and […]

This article is password protected.

To view the content, please enter your password in the field below